Elanco Animal Health (NYSE:ELAN) Price Target Raised to $23.00

Elanco Animal Health (NYSE:ELAN) had its price objective upped by Stifel Nicolaus from $18.00 to $23.00 in a research report released on Wednesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

ELAN has been the subject of several other research reports. Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Saturday, July 5th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. UBS Group boosted their price target on Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, August 8th. William Blair upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Finally, Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $18.33.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $19.63 on Wednesday. The firm has a 50 day moving average of $17.19 and a two-hundred day moving average of $13.73. The stock has a market capitalization of $9.75 billion, a PE ratio of 22.82, a P/E/G ratio of 3.51 and a beta of 1.62. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $19.70.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.Elanco Animal Health’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts predict that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently bought and sold shares of the stock. Nuveen LLC acquired a new stake in Elanco Animal Health during the 1st quarter valued at $115,212,000. Dimensional Fund Advisors LP grew its stake in Elanco Animal Health by 14.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Elanco Animal Health by 322.0% during the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after buying an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Finally, ASR Vermogensbeheer N.V. bought a new stake in shares of Elanco Animal Health in the first quarter worth $23,744,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.